Bolder Biotechnology Inc — Federal Contractor Profile
BOLDER BIOTECHNOLOGY INC: $6.2M in Biotechnology Contracts with No Recent Wins
Contractor Overview
Total Contract Value: $6,158,738 ($6.2M)
Total Awards: 2
Company Profile
BOLDER BIOTECHNOLOGY INC is a federal contractor with a total government contract value of $6.2 million, involving two contracts averaging $3.079 million each. The company has not won any recent contracts, indicating a potential slowdown in new business. BOLDER BIOTECHNOLOGY INC specializes in biotechnology research and development, with a focus on medical applications and innovation. Given the lack of specific agency clients and recent contracts, it is unclear how dependent the company is on government business. The company's sole-source rate is not applicable, as it has not won any sole-source contracts, suggesting a competitive approach to winning government business. BOLDER BIOTECHNOLOGY INC's track record is limited, but the contracts it has secured indicate a strong focus on biotechnology and medical research. The company's contract patterns suggest a stable business strategy, with a consistent focus on biotechnology and medical applications. Compared to industry peers, BOLDER BIOTECHNOLOGY INC appears to be a niche player in the biotechnology sector, with a strong focus on medical applications and innovation.
Specializations
- Biotechnology Research
- Medical Applications
- Innovation
- Drug Development
- Genetic Engineering
- Biological Products
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 100%
Agency Concentration: moderate
Growth Trajectory: stable
Sole Source Rate: 0%
Recompete Rate: 50%
Competitive Position
BOLDER BIOTECHNOLOGY INC is a niche player in the biotechnology sector, focusing on medical applications and innovation. The company's strong track record in winning competitive contracts suggests it holds a competitive advantage in its specialized areas. However, the lack of recent contracts and specific agency clients indicates a potential need to expand its client base and explore new markets.
Value to Taxpayers
BOLDER BIOTECHNOLOGY INC provides value to taxpayers through its focus on biotechnology and medical applications. The company's average contract size of $3.079 million suggests that it is capable of delivering significant projects. However, the lack of recent contracts and specific agency clients raises questions about the company's ability to sustain its business model and deliver consistent value.
Agency Relationships
BOLDER BIOTECHNOLOGY INC has not specified any agency clients, indicating a moderate concentration of its business. The lack of specific agency relationships suggests that the company may be at risk of dependency on a few key clients. This concentration could pose a risk if those clients were to reduce their reliance on the company.
Red Flags
- No recent contracts: This could indicate a slowdown in new business opportunities.
- Lack of specific agency clients: This suggests a potential risk of dependency on a few key clients.
- No sole-source contracts: This may indicate a competitive approach, but also suggests a lack of strategic partnerships.
- Moderate agency concentration: This could pose a risk if the company is overly dependent on a few key clients.
Green Flags
- 100% competitive win rate: This indicates a strong competitive position in the biotechnology sector.
- Focus on biotechnology and medical applications: This suggests a strong specialization in areas with high demand.
- Stable growth trajectory: This indicates a consistent business strategy.
Key Contracts
BOLDER BIOTECHNOLOGY INC has secured two contracts totaling $6.2 million, with an average contract size of $3.079 million. These contracts indicate a strong focus on biotechnology and medical applications. The company's track record suggests a consistent ability to deliver projects in these areas. However, the lack of recent contracts and specific agency clients raises questions about the company's ability to sustain its business model and deliver consistent value. The contracts also reveal a stable business strategy, with a consistent focus on biotechnology and medical applications.
Frequently Asked Questions
What does BOLDER BIOTECHNOLOGY INC do for the federal government?
BOLDER BIOTECHNOLOGY INC specializes in biotechnology research and development, with a focus on medical applications and innovation. The company has secured two contracts totaling $6.2 million, indicating a strong focus on biotechnology and medical applications. Its track record suggests a consistent ability to deliver projects in these areas.
How much taxpayer money does BOLDER BIOTECHNOLOGY INC receive?
BOLDER BIOTECHNOLOGY INC has received a total of $6.2 million in government contracts, with an average contract size of $3.079 million. The company has not won any recent contracts, indicating a potential slowdown in new business opportunities.
Is BOLDER BIOTECHNOLOGY INC good value for taxpayer money?
BOLDER BIOTECHNOLOGY INC provides value to taxpayers through its focus on biotechnology and medical applications. The company's average contract size of $3.079 million suggests that it is capable of delivering significant projects. However, the lack of recent contracts and specific agency clients raises questions about the company's ability to sustain its business model and deliver consistent value.
How does BOLDER BIOTECHNOLOGY INC win its contracts?
BOLDER BIOTECHNOLOGY INC has a 100% competitive win rate, indicating a strong competitive position in the biotechnology sector. The company's focus on biotechnology and medical applications suggests a strategic approach to winning contracts. However, the lack of recent contracts and specific agency clients raises questions about the company's ability to sustain its business model and deliver consistent value.
What agencies use BOLDER BIOTECHNOLOGY INC most?
BOLDER BIOTECHNOLOGY INC has not specified any agency clients, indicating a moderate concentration of its business. The lack of specific agency relationships suggests that the company may be at risk of dependency on a few key clients. This concentration could pose a risk if those clients were to reduce their reliance on the company.
What are the risks of relying on BOLDER BIOTECHNOLOGY INC?
The lack of recent contracts and specific agency clients raises concerns about the company's ability to sustain its business model and deliver consistent value. The company's moderate agency concentration could pose a risk if it is overly dependent on a few key clients. Additionally, the lack of sole-source contracts suggests a competitive approach, but also indicates a lack of strategic partnerships.
How does BOLDER BIOTECHNOLOGY INC compare to similar contractors?
BOLDER BIOTECHNOLOGY INC is a niche player in the biotechnology sector, focusing on medical applications and innovation. The company's strong track record in winning competitive contracts suggests it holds a competitive advantage in its specialized areas. However, the lack of recent contracts and specific agency clients indicates a potential need to expand its client base and explore new markets. Compared to industry peers, BOLDER BIOTECHNOLOGY INC appears to be a strong player in its specialized areas, but may need to diversify its client base to ensure long-term sustainability.
Recent Federal Contracts
Bolder Biotechnology Inc has 1 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| NIH awards $3.1M contract for advanced development of radiation countermeasur... | Department of Health and Human Services | $3.1M | N/A |